An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.

Urination Disorders Clinical Trial

Official title:
A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride) for the Treatment of Lower Urinary Tract Symptoms.

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of oxybutynin extended release tablets 10 mg plus tamsulosin HCl 0.4 mg in the treatment of lower urinary tract symptoms as measured by change of the total International Prostate Symptom Score (I-PSS) from baseline to Week 12 or the Final Visit.

Clinical Trial Description

The objective of this double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), randomized (patients are assigned different treatments based on chance), parallel group trial is to evaluate the safety and effectiveness of oxybutynin extended release tablets 10 mg per day for 12 weeks in conjunction with an alpha-blocker for the treatment of lower urinary tract symptoms (LUTS). The hypothesis of the study is that oxybutynin extended release tablets 10 mg plus tamsulosin 0.4 mg will be more effective than tamsulosin 0.4 mg plus placebo in the treatment of lower urinary tract symptoms as measured by change of the total International Prostate Symptom Score (I-PSS) from baseline to Week 12 or the Final Visit. Safety assessments include Peak Flow Rate (PFR) and Post-Void Residual (PVR) volume, adverse events, vital signs and physical exams. Patients will receive oxybutynin extended release 10 mg plus tamsulosin 0.4 mg or placebo plus tamsulosin 0.4 mg every day for 12 weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00338624
Study type	Interventional
Source	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	May 2004
Completion date	June 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01833663` - Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women	Phase 4
Recruiting	`NCT05989646` - Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children	N/A
Recruiting	`NCT04114266` - Registry for Patients Undergoing AUS Surgery for Female SUI Due to ISD
Completed	`NCT02130843` - Tiemann Mounted Urodynamic Catheter Technique for Difficult Bladder Catheterization	N/A
Active, not recruiting	`NCT01642979` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Phase 2
Completed	`NCT00214045` - Rigid Versus Flexible Cystoscopy in Women	N/A
Active, not recruiting	`NCT01760096` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Phase 2
Completed	`NCT02266524` - Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders	Phase 1
Completed	`NCT02291432` - Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery	Phase 1/Phase 2
Not yet recruiting	`NCT03325543` - Can Women Correctly Contract Their Pelvic Floor Muscles After to Receive Verbal Instructions and Vaginal Palpation?	N/A